BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 17329192)

  • 1. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
    Martín M; Ruiz A; Muñoz M; Balil A; García-Mata J; Calvo L; Carrasco E; Mahillo E; Casado A; García-Saenz JA; Escudero MJ; Guillem V; Jara C; Ribelles N; Salas F; Soto C; Morales-Vasquez F; Rodríguez CA; Adrover E; Mel JR;
    Lancet Oncol; 2007 Mar; 8(3):219-25. PubMed ID: 17329192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
    Pallis AG; Boukovinas I; Ardavanis A; Varthalitis I; Malamos N; Georgoulias V; Mavroudis D
    Ann Oncol; 2012 May; 23(5):1164-1169. PubMed ID: 21937705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
    Morabito A; Filippelli G; Palmeri S; Cascinu S; Ferraù F; Zagonel V; Gattuso D; Catalano V; Capaccetti B; Franciosi V; Accurso V; Scinto F; Gasparini G
    Breast Cancer Res Treat; 2003 Mar; 78(1):29-36. PubMed ID: 12611454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.
    Gioulbasanis I; Saridaki Z; Kalykaki A; Vamvakas L; Kalbakis K; Ignatiadis M; Amarantidis K; Kakolyris S; Georgoulias V; Mavroudis D
    Anticancer Res; 2008; 28(5B):3019-25. PubMed ID: 19031950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.
    Stemmler HJ; diGioia D; Freier W; Tessen HW; Gitsch G; Jonat W; Brugger W; Kettner E; Abenhardt W; Tesch H; Hurtz HJ; Rösel S; Brudler O; Heinemann V
    Br J Cancer; 2011 Mar; 104(7):1071-8. PubMed ID: 21407218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.
    Wang J; Zheng R; Wang Z; Yang Y; Wang M; Zou W
    Med Sci Monit; 2017 Sep; 23():4657-4664. PubMed ID: 28957036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and toxicity of gemcitabine combined vinorelbine on metastatic breast cancer: a report of 34 cases].
    Zhou NN; Teng XY; Jiang WQ; Liu DG
    Ai Zheng; 2007 Dec; 26(12):1373-6. PubMed ID: 18076805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
    Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
    Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Andres R; Mayordomo JI; Lara R; Lastra R; Ortega E; Polo E; Lambea J; Isla D; Saenz-Cusi A; Escudero P; Tres A
    Clin Breast Cancer; 2005 Jun; 6(2):158-62. PubMed ID: 16001994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
    Zhang P; Sun T; Zhang Q; Yuan Z; Jiang Z; Wang XJ; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Peng R; Yan M; Zhang S; Huang J; Tang L; Qiu R; Xu B;
    Lancet Oncol; 2017 Mar; 18(3):371-383. PubMed ID: 28209298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial.
    Lobo F; Virizuela JA; Dorta FJ; Florián J; Lomas M; Jiménez E; López P; Casado V; Léon A; Estévez LG; Dómine M;
    Clin Breast Cancer; 2003 Apr; 4(1):46-50. PubMed ID: 12744758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer.
    Park IH; Ro J; Lee KS; Kim SN; Yun YH; Nam BH
    Invest New Drugs; 2010 Oct; 28(5):659-69. PubMed ID: 19575146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study.
    Antón A; Barnadas A; Florián J; Ribelles N; Lomas M; Lao J; González-Quintás A; Margelí M; Paules AB; Gayo J; Ramos M;
    Clin Transl Oncol; 2011 Apr; 13(4):281-6. PubMed ID: 21493190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and vinorelbine combination in patients with metastatic breast cancer.
    Sanal SM; Gokmen E; Karabulut B; Sezgin C
    Breast J; 2002; 8(3):171-6. PubMed ID: 12047474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Dong N; Wang M; Li H; Cui Y; Guo Q
    Cancer Chemother Pharmacol; 2012 May; 69(5):1315-22. PubMed ID: 22307763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.